Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 142 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluzone High Dose Vaccine Clear all

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Metairie, Louisiana

Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions: Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more

Conditions: Central Nervous System Neoplasm
Interventions: trivalent influenza vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Winston-Salem, North Carolina

Conditions: Influenza
Interventions: Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 4
States / cities: Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 9,172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 96
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 86 more

Conditions: Inflammatory Bowel Disease (IBD)
Interventions: Standard dose Influenza vaccine (SDIV), High dose influenza vaccine (HDIV); Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 64 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: Influenza VLP Vaccine (recombinant), Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Tucson, Arizona • Lenexa, Kansas • Louisville, Kentucky + 1 more

Conditions: Healthy Volunteer
Interventions: Flucelvax, Fluvirin, Fluzone High Dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Conditions: Heart Failure, Myocardial Infarction
Interventions: High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5,388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 127
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 93 more

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Glendale, Arizona • San Diego, California • Vista, California + 3 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, FLU HD vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV, Cancer
Interventions: Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 21 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 944 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Portland, Oregon • Temple, Texas

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Human, Transplantation Infection
Interventions: influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose; Biological
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Search by objective public record fields.

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

2017 A/H7N9 IIV Revaccination

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

A Study of Updated mRNA Seasonal Influenza Vaccines

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.